Last reviewed · How we verify
NCT06968221
Bovine Reinforcement in Stomach, Colorectal and Lung Operation
Phase 3 trial testing Bioabsorbable Staple Line Reinforcemen in Rectal Cancer Stage III in 172 participants. Currently enrolling.
1 September 2025
Quick facts
| Lead sponsor | Shanghai Cingularbio Co. Ltd |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 172 |
| Start date | 1 May 2025 |
| Primary completion | 1 September 2025 |
| Estimated completion | 31 October 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Bioabsorbable Staple Line Reinforcemen
Conditions studied
- Rectal Cancer Stage III — all drugs for Rectal Cancer Stage III →
- Lung Cancer Stage III — all drugs for Lung Cancer Stage III →
Sponsor
Shanghai Cingularbio Co. Ltd
Who can join
Adults 18 to 75, any sex, with Rectal Cancer Stage III or Lung Cancer Stage III. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary purpose of this prospective, randomized multicenter center study is to evaluate and compare the outcomes of stomach,colorectal and lung anastomoses reinforced with a bioabsorbable staple line reinforcement material compared with standard non-reinforced techniques with respect to the incidence of postoperative hemorrage rate, anastomotic leakage, if applicable.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06968221
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Rectal Cancer Stage III
Currently open trials in the same condition.
- NCT06802172 — Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial · NA · recruiting
- NCT06565052 — The Impact of PReOPerative Exercise and NutritionaL Optimization on Perioperative Outcomes for Patients Undergoing Treat · NA · recruiting
- NCT06254521 — The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer · Phase 2 · recruiting
- NCT05148767 — UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer · Phase 4 · recruiting
- NCT04246684 — Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients · Phase 3 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06968221 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Cingularbio Co. Ltd
- Last refreshed: 15 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06968221.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing